Home » Stocks » CGEN

Compugen Ltd. (CGEN)

Stock Price: $12.79 USD -0.05 (-0.39%)
Updated December 3, 4:00 PM EST - Market closed

CGEN Stock Price Chart

Key Info

Market Cap 1.06B
Revenue (ttm) n/a
Net Income (ttm) -27.34M
Shares Out 63.64M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $12.79
Previous Close $12.84
Change ($) -0.05
Change (%) -0.39%
Day's Open -
Day's Range 12.69 - 13.37
Day's Volume 0
52-Week Range 0.00 - 13.37

CGEN Stock News

PRNewsWire - 3 weeks ago

HOLON, Israel, Nov. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that managem...

Seeking Alpha - 3 weeks ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

HOLON, Israel, Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addit...

PRNewsWire - 2 months ago

HOLON, Israel, Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd.

PRNewsWire - 3 months ago

HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd.

PRNewsWire - 3 months ago

HOLON, Israel, Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd.

Seeking Alpha - 4 months ago

Compugen Ltd (CGEN) CEO Anat Dayag on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 4 months ago

HOLON, Israel, July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial r...

Seeking Alpha - 4 months ago

Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment

PRNewsWire - 4 months ago

HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the C...

Seeking Alpha - 6 months ago

Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

PRNewsWire - 6 months ago

HOLON, Israel, June 1, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U....

The Motley Fool - 6 months ago

Here are the hottest companies coming up in the biotech sector next month.

Other stocks mentioned: RHHBY, VRTX
Zacks Investment Research - 6 months ago

Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

Zacks Investment Research - 6 months ago

Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 6 months ago

Roche's Upcoming Phase 2 TIGIT Results At ASCO Could Read Through To Compugen's COM902 TIGIT Candidate

Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for May 8th

Other stocks mentioned: CHGG, GNMK
Seeking Alpha - 6 months ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 6 months ago

Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.

Zacks Investment Research - 7 months ago

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 7 months ago

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

24/7 Wall Street - 8 months ago

When the financial markets enter their once-a-decade crisis mode, it often feels impossible to think rationally and to make normal investing decisions.

The Motley Fool - 8 months ago

Two patients treated with one of the biotech's drugs had partial responses.

Seeking Alpha - 9 months ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Compugen Ltd.: Upcoming Catalysts In 2020 And 2021

24/7 Wall Street - 10 months ago

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...

Other stocks mentioned: GLUU, GME, GRPN, IDXG, MEET, OGI, RTIX, SYBX, ZNGA
Investopedia - 10 months ago

Compugen shares rebounded Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $10 price target.

Zacks Investment Research - 11 months ago

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

Other stocks mentioned: ACAD, CUE, EPZM, QURE
Zacks Investment Research - 1 year ago

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2019 Results - Earnings Call Transcript

About CGEN

Compugen, a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its thera... [Read more...]

Industry
Biotechnology
IPO Date
Aug 11, 2000
CEO
Anat Cohen-Dayag
Employees
61
Stock Exchange
NASDAQ
Ticker Symbol
CGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Compugen is 20.38, which is an increase of 59.34% from the latest price.

Price Target
$20.38
(59.34% upside)